report-bg

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

Analysis by Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids, and Others); by Disease Indication (Ulcerative Colitis and Crohn’s Disease); and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

Buy Now
Report ID: 4648 | Published On: Dec 26, 2022
Request Free Sample Copy

Major Macro-Economic Indicators Impacting the Market Growth

healthcare expenditure graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5,355.79, which grew from USD 3,515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in the upcoming years.


IDB market overview image
Get more information on this report: Request Sample PDF

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Growth Drivers and Challenges
cscs

Growth Drivers

  • Growing Prevalence of Crohn’s Disease– As many as 780,000 people in the United States are affected by Crohn's disease, making it a widespread ailment. The disease is most prevalent in people between the ages of 15 and 35, with 25% of cases being identified by age 20. Crohn's disease is a kind of inflammatory bowel disease (IBD). It causes swelling of the tissues (inflammation) in the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Hence, the increasing cases of Crohn’s disease is estimated to drive the market growth.

  • Increasing Investment in Research and Development – For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD245 billion in 2020 from 2019.

  • Growing Spending on Rare Disease – It was observed that approximately USD 997 billion is spent on the prevention, diagnosis, treatment, and awareness of rare diseases, of which USD 449 billion goes directly toward medical expenses and around USD 437 billion accounted for indirect medical costs.

  • Rising Healthcare Expenditure – In 2020, general government spending on health in the EU reached USD 1 074 billion, or 8.0% of GDP.

  • Increasing Cases of Fecal Incontinence – It was found that fecal incontinence affects between 18 to 33 patients out of every 100 hospitalized patients and 50 to 70 patients out of every 100 nursing care residents, respectively.

Challenges

  • Lack of Awareness Among People Regarding Inflammatory Bowel Disease (IBD)
  • High Treatment Cost
  • Lack of Reimbursement Facility for the Treatment of IBD

The IBD (Ulcerative Colitis and Crohn's Disease) treatment market is segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Out of these, the hospital pharmacies segment is estimated to hold the largest market share by the end of 2033 owing to rising patient flow in the hospitals. Further, the IBD is anticipated to expand throughout the projected period owing to the increasing spending on healthcare across the globe as a result of doctors' increasing caution and suggestions of tests for the parents. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).


Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Regional Synopsis

Regionally, the global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America region is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed to the U.S. and Canada's high prevalence and rising incidence of ulcerative colitis and Crohn's disease, as well as their developed healthcare systems and high risk of lifestyle-related variables. It was found during research that IBD, which includes Crohn's disease and ulcerative colitis, has been identified in an estimated 3.1 million individuals (1.3%) in the United States.

IDB market share image

Get more information on this report:Download Sample PDF

The global IBD (Ulcerative Colitis and Crohn's Disease) treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook


Market Segmentation

Our in-depth analysis of the global IBD (Ulcerative Colitis and Crohn's Disease) treatment market includes the following segments:

     By Drug Class

  • TNF Inhibitors
  • Aminosalicylates
  • Integrin Antagonists
  • Corticosteroid
  • Others

    By Disease Indication

  • Ulcerative Colitis
  • Crohn’s Disease

    By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


healthcare expenditure graph
Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

    • Bristol Myers Squibb Company (BMS)
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • AbbVie Inc.
    • Novartis AG
    • UCB, Inc.
    • Biogen, Inc.
    • Pfizer, Inc.
    • Janssen Global Services, LLC
    • Takeda Pharmaceutical Company Limited
    • CELLTRION Inc.

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the IDB (ulcerative colitis and Crohn's disease) market?

Ans: Increasing prevalence of Crohn’s disease and the rising cases of ulcerative colitis are the main factor driving the growth of the IBD (Ulcerative Colitis and Crohn's Disease) treatment market.

2) What would be the CAGR of IDB (ulcerative colitis and Crohn's disease) market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 – 2033.

3) What are the challenges affecting the IDB (ulcerative colitis and Crohn's disease) market growth?

Ans: High treatment cost and lack of awareness among people regarding IBD are the main challenges to market growth.

4) Which region will provide more business opportunities for growth of IDB (ulcerative colitis and Crohn's disease) market in future?

Ans: The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

5) Who are the major players dominating the IDB (ulcerative colitis and Crohn's disease) market?

Ans: The major players in the market are Bristol Myers Squibb Company (BMS), Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB, Inc., Biogen, Inc., Pfizer, Inc., Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, CELLTRION Inc.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the IBD (Ulcerative Colitis and Crohn's Disease) treatment market?

Ans: The market is segmented by drug class, disease indication, distribution channel, and by region.

8) Which segment captures the largest market size in distribution channel segment in the IBD (Ulcerative Colitis and Crohn's Disease) treatment market?

Ans: The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample